Publications by authors named "Peggy L Lin"

Claim this Profile
M
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Joshua Richter, Peggy L Lin, Viviana Garcia-Horton, Patricia Guyot, Erin Singh

Cancer Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Fredrik Schjesvold, Paul G Richardson, Thierry Facon, Adrián Alegre, Andrew Spencer, Peggy L Lin

Haematologica· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Fredrik H Schjesvold, Paul G Richardson, Thierry Facon, Adrián Alegre, Andrew Spencer, Peggy L Lin

Haematologica· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.
Xingdi Hu, Kingsley P Wildman, Subham Basu, Peggy L Lin, Clare Rowntree

Health Econ Rev· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
Nanxin Li, Yanni Hao, Jipan Xie, Peggy L Lin, Valerie Koo

Clin Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.
Peggy L Lin, Yanni Hao, Jipan Xie, Nanxin Li, Yichen Zhong

Cancer Med· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Peggy L Lin, Yanni Hao, Jipan Xie, Nanxin Li, Erika Ohashi

Expert Opin Pharmacother· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Jipan Xie, Yanni Hao, Nanxin Li, Peggy L Lin, Erika Ohashi

Exp Hematol Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer.
Yan Song, Yanni Hao, Alexander R Macalalad, Peggy L Lin, James E Signorovitch

Breast Cancer (Auckl)· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Nanxin Li, Yanni Hao, Jipan Xie, Peggy L Lin, Zhou Zhou

Curr Med Res Opin· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Yanni Hao, Peggy L Lin, Jipan Xie, Nanxin Li, Valerie Koo, Jaqueline Rogerio

J Comp Eff Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Jipan Xie, Yanni Hao, Nanxin Li, Peggy L Lin, Erika Ohashi

Curr Med Res Opin· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
Nanxin Li, Yanni Hao, Jipan Xie, Peggy L Lin, Valerie Koo

Int J Breast Cancer· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.
Michael K Wong, Eric Jonasch, Sumanta K Pal, James E Signorovitch, Peggy L Lin

Expert Opin Pharmacother· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Alexander R Macalalad, Yanni Hao, Peggy L Lin, James E Signorovitch, Eric Q Wu, Caroline Kelley

Curr Med Res Opin· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.
James E Signorovitch, Nicholas J Vogelzang, Sumanta K Pal, Peggy L Lin, Daniel J George

Curr Med Res Opin· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Eric Jonasch, James E Signorovitch, Peggy L Lin, Zhimei Liu, Ken Culver

Curr Med Res Opin· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis